<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850850</url>
  </required_header>
  <id_info>
    <org_study_id>2006-002497-22</org_study_id>
    <nct_id>NCT00850850</nct_id>
  </id_info>
  <brief_title>Physostigmine After General Anesthesia</brief_title>
  <official_title>The Use of Physostigmine in Elderly Patients in the Postoperative Recovery-phase After General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recovery after general anaesthesia is often prolonged in the elderly. This group is
      particularly exposed to post-operative confusion. This has negative personal consequences as
      well as consequences for the postoperative care for these patients.

      The hypothesis is that physostigmine will decrease the amount of time in the post-anaesthesia
      care unit (PACU ), the postoperative amount of pain and shivering and finally post-operative
      confusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researchers wish to investigate the use of physostigmine in the elderly patients (age &gt;
      60 yrs, ASA I-III) in the postoperative recovery-phase after general anesthesia.

      Apart from the beneficial effects for the patient, the lessened amount of time in the PACU
      will release caregiving resources and thereby increase the efficacy of the PACU.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The readiness to be released from the PACU (assessed by the normal guidelines) It should be noted that for safety reasons the patients remained in the PACU for at least 60 minutes</measure>
    <time_frame>60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain, shivering and nausea will also be registered on the standardized form as well as a multiple of physiological measurements. A follow-up will be performed after 12 hours from release from the PACU</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <condition>Anesthesia Recovery Period</condition>
  <arm_group>
    <arm_group_label>Physostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 mg of physostigmine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>physostigmine</intervention_name>
    <description>1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.</description>
    <arm_group_label>Physostigmine</arm_group_label>
    <other_name>Fysostigmin; Methylcarbamate; Erserine; Eserolein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic sodium chloride solution</intervention_name>
    <description>Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.</description>
    <arm_group_label>NaCl</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for surgical acute or elective operation

          -  General anesthesia.

          -  ASA physical status I-III

          -  Age &gt; 60 years

        Exclusion Criteria:

          -  Asthma and chronic pulmonary diseases

          -  Glaucoma

          -  Diabetics

          -  Any history of neurological and psychiatric disorder

          -  Parkinson's disease

          -  Disorders of the gastrointestinal and urogenital tracts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Pott, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank Pott, MD</last_name>
    <phone>+4535313531</phone>
    <phone_ext>4358</phone_ext>
    <email>frank.pott@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carsten M Pedersen, MSN</last_name>
    <phone>+4535313983</phone>
    <phone_ext>4845</phone_ext>
    <email>carstenmp@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Copenhagen NV</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten M Pedersen, cand.cur.</last_name>
      <phone>+4535313983</phone>
      <email>cped0070@bbh.regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2009</study_first_posted>
  <last_update_submitted>May 26, 2010</last_update_submitted>
  <last_update_submitted_qc>May 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Frank Pott</name_title>
    <organization>ICU</organization>
  </responsible_party>
  <keyword>PACU</keyword>
  <keyword>Physostigmine</keyword>
  <keyword>Recovery</keyword>
  <keyword>Postanesthesia Nursing</keyword>
  <keyword>Wakefulness</keyword>
  <keyword>General anesthesia</keyword>
  <keyword>General Anesthetics</keyword>
  <keyword>Postoperative Period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Physostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

